Mμ and D2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats

Alcohol

Volumn 18, Issue 2-3, 1999, Pages 225-233

  Myers, R D ^a   Robinson, D E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Alcohol drinking; Alcoholism; Antisense Oligodeoxynucleotide (ODN); Dopamine2 receptors; Genetic drinking rats; Microinjections; M receptors; Nucleus accumbens

Indexed keywords

ALCOHOL; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; DOPAMINE 2 RECEPTOR; MUSCARINIC RECEPTOR; MU OPIATE RECEPTOR;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRINKING BEHAVIOR; FEMALE; GENETIC PREDISPOSITION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; RAT; ALCOHOLISM; ANIMAL; BREEDING; DRUG EFFECT; GENETICS; SPRAGUE DAWLEY RAT;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; BREEDING; FEMALE; MALE; NUCLEUS ACCUMBENS; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID, MU;

EID: 0032588305     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-8329(99)00015-4     Document Type: Article

References (102)

1. Acquas E., Meloni M., Di Chiara G. Blockade of delta-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Europ. J. Pharmacol. 230:1993;239-241.
2. Ahlenius S., Carlsson A., Engel J., Svensson T., Sodersten P. Antagonism by alpha-methyltyrosine of ethanol-induced stimulation and euphoria in man. Psychopharmacol. 112:1973;503-510.
3. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:1997;12-18.
4. Albert P.R., Morris S.J. Antisense knockouts. molecular scalpels for the dissection of signal transduction Trends Pharmacol. Sci. 7:1994;250-254.
5. 2 receptors in the nucleus accumbens of the rat. Brain Res. 501:1989;389-391.
6. Benjamin D., Grant E., Pohorecky L. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 621:1993;137-140.
7. Biggs T.A.G., Myers R.D. Adenosine A1 receptor antisense infused in striatum of rats. actions on alcohol induced locomotor impairment, blood alcohol and temperature Alcohol. 14:1997;617-622.
8. Biggs T.A.G., Myers R.D. Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol preferring P rats. Pharmacol. Biochem. Behav. 60:1998;1-7.
9. Blanchard B., Glick S. Sex differences in mesolimbic dopamine responses to ethanol and relationship to ethanol intake in rats. Recent Dev. Alcohol. 12:1995;231-241.
10. Blum K., Briggs A., Trachtenberg M., Delallo L., Wallace J. Enkephalinase inhibition. regulation of ethanol intake in genetically predisposed mice Alcohol. 4:1987;449-456.
11. Brog J., Salypongse A., Deutch A., Zahm D. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum. immunohistochemical detection of retrogradely transported fluoro-gold J. Comp. Neurol. 338:1993;255-278.
12. Brown Z., Gill K., Abitbol M., Amit Z. Lack of effect of dopamine receptor blockade on voluntary ethanol consumption in rats. Behav. Neural Bio. 36:1982;291-294.
13. Cashaw J.L. Tetrahydropapaveroline in brain regions of rats after acute ethanol administration. Alcohol. 10:1993;133-138.
14. Cashaw J., Geraghty C., McLaughlin B., Davis V. Effect of acute ethanol administration on brain levels of tetrahydro-papaveroline in L-dopa-treated rats. J. Neurosci. Res. 18:1987;497-503.
15. Chen X.H., Adams J.U., Geller E.B., DeRiel J.K., Adler M.W., Liu-Chen L.Y. An antisense oligodeoxynucleotide to μ-opioid receptors inhibits Mμ-opioid receptor agonist-induced analgesia in rats. Europ. J. Pharmacol. 275:1995;105-108.
16. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.A. The application of antisense oligonucleotide technology to the brain. some pitfalls Cell. Mol. Neurobiol. 14:1994;507-521.
17. Clow A., Stolerman I.P., Murray R.M., Sandler M. Ethanol preference in rats. increased consumption after intraventricular administration of tetrahydropapaveroline Neuropharmacol. 22:1983;563-565.
18. Critcher E.C., Lin C.I., Patel J., Myers R.D. Attenuation of alcohol drinking in tetrahydroisoquinoline-treated rats by morphine and naltrexone. Pharmacol. Biochem. Behav. 18:1983;225-229.
19. Diana M., Pistis M., Carboni S., Gessa G., Rossetti Z. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats. electrophysiological and biochemical evidence Proc. Natl. Acad. Sci. 90:1993;7966-7969.
20. DiChiara G., Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates. studies with transcerebral dialysis in freely moving rats Ann. N.Y. Acad. Sci. 473:1986;367-381.
21. Dolnick B.J. Antisense agents in pharmacology. Biochem. Pharmacol. 40:1990;671-675.
22. 2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats. Alcohol. 10:1993;207-212.
23. George S.R., Fan T., Ng G., Jung S.Y., O'Dowd B.F., Naranjo C.A. Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption. reversal by increasing synaptic dopamine J. Pharmacol. Exp. Ther. 273:1995;373-379.
24. Gongwer M.A., Murphy J.M., McBride W.J., Lumeng L., Li T.K. Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats. Alcohol. 6:1989;317-320.
25. 2 blockade on ethanol intake selected and unselected strains of rats. Alcohol. 13:1996;273-279.
26. Heilig M., Schlingensiepen K. Antisense oligodeoxynucleotides as novel neuropharmacological tools for selective expression blockade in the brain. Latchman D.S. Genetic Manipulation of the Nervous System. 1996;249-263 Academic Press Ltd, New York.
27. Heimer L., Zahm D., Churchill L, Kalivas P., Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neurosci. 41:1991;89-125.
28. Idanpaan-Heikkila J.J., Rauhala P., Mannisto P.T. Mμ- and delta-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. Europ. J. Pharmacol. 284:1995;227-230.
29. Jones S., O'Dell S., Marshall J., Wightman R. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse. 23:1996;224-231.
30. Koob G.F. Drugs of abuse. anatomy, pharmacology and function of reward pathways Trends Pharmacol. Sci. 13:1992;177-184.
31. Koob G., Bloom F. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
32. Landgraf R. Intracerebrally released vasopressin and oxytocin. measurement, mechanisms and behavioural consequences J. Neuroendocrinol. 7:1995;243-253.
33. 2A receptors in alcohol drinking. preference in HAD rats is inhibited by combination treatment with naltrexone and amperozide Alcohol. 13:1996;53-57.
34. Lankford M.F., Roscoe A.K., Pennington S.N., Myers R.D. Drinking of high concentrations of ethanol versus palatable fluids in alcohol-preferring (P) rats. valid animal model of alcoholism Alcohol. 8:1991;293-299.
35. LeMarquand D., Pihl R.O., Benkelfat C. Serotonin and alcohol intake, abuse, and dependence. findings of animal studies Biol. Psychiatry. 36:1994;395-421.
36. Lin C.I., Myers R.D. Reversal of THP-induced alcohol drinking in the rat by systemic naloxone and morphine. Alcohol Clin. Exp. Res. 2:1978;188.
37. Lograno D., Matteo F., Trabucchi M., Govoni S., Cagiano R., Lacomba C., Cuomo V. Effects of chronic ethanol intake at a low dose on the rat brain dopaminergic system. Alcohol. 10:1993;45-49.
38. Lopez-Valpuesta F.J., Nyce J.W., Myers R.D. Neuropeptide Y and Y1 receptor antisense injected centrally. actions on feeding, temperature, body weight and circadian activity in rats NeuroRep. 7:1996;2781-2784.
39. Lopez-Valpuesta F.J., Nyce J., Griffin T.A., Ice J., Myers R.D. Antisense to NPY-Y1 demonstrates that Y1 receptors in the hypothalamus underlie NPY hypothermia and feeding in rats. Proc. R. Soc. Lond. B. 263:1996;881-886.
40. 2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol. 10:1993;387-390.
41. McBride W.J., Murphy J.M., Lumeng L., Li T.K. Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats. Alcohol. 7:1990;199-205.
42. McBride W., Murphy J., Gatto G., Levy A., Yoshimoto K., Lumeng L., Li T. CNS mechanisms of alcohol self-administration. Alc. Alcohol. Suppl. 2:1993;463-467.
43. Meert T., Clincke G. 7-OHDPAT and alcohol consumption, withdrawal and discrimination stimulus properties in rats. Alcohol Alcohol. 29:1994;489-492.
44. Melchior C., Collins M. The route and significance of endogenous synthesis of alkaloids in animals. CRC Crit. Rev. Toxicol. 9:1982;313-356.
45. Melchior C.L., Myers R.D. Preference for alcohol evoked by tetrahydropapaveroline (THP) chronically infused in the cerebral ventricle of the rat. Pharmac. Biochem. Behav. 7:1977;19-35.
46. Melchior C.L., Simpson C.W., Myers R.D. Dopamine release within forebrain sites perfused with tetrahydroisoquinolines or tryptoline in the rat. Brain Res. Bull. 3:1978;631-634.
47. Meredith G., Agolia R., Arts M., Groenewegen H., Zahm D. Morphological differences between projection neurons of the core and shell in the nucleus accumbens of the rat. Neurosci. 50:1992;149-162.
48. Morgan R., Edge M., Colman A. A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligos. Nucleic Acids Res. 21:1993;4615-4620.
49. Morris M., Lucion A.B. Antisense oligonucleotides in the study of neuroendocrine systems. J. Neuroendocrinol. 7:1995;493-500.
50. Morvan F., Porumb H., Degols G., Lefevre I., Pampon A., Sproat B.S., Rayner B., Malvy C., Lebleu B., Imbach J. Comparative evaluation of seven oligonucleotide analogues as a potential antisense agents. J. Med. Chem. 36:1993;280-287.
51. Myers R.D. Methods for chemical stimulation of the brain. Myers R.D. Methods in Psychobiology. Vol. 1. 1971;247-280 Academic Press, London.
52. Myers R.D. Handbook of drug and chemical stimulation of the brain. 1974;Van Nostrand Reinhold, New York.
53. Myers R.D. Psychopharmacology of alcohol. Ann. Rev. Pharmacol. Toxicol. 18:1978;125-144.
54. Myers R.D. Isoquinolines, beta-carbolines and alcohol drinking. involvement of opioid and dopaminergic mechanisms Experientia. 45:1989;436-443.
55. Myers R.D. Neurobiological basis of alcohol reinforcement and drinking. Engs R. Controversy in the addiction field. 1990;25-38 Kendall/Hunt, Dubuque, Iowa.
56. Myers R.D., Critcher E. Naloxone alters alcohol drinking induced in the rat by tetrahydropapaveroline (THP) infused ICV. Pharmac. Biochem. Behav. 16:1982;827-836.
57. Myers R.D., Lankford M.F. Suppression of alcohol preference in high alcohol drinking rats. effects of amperozide versus naltrexone Neuropsychopharmacol. 14:1996;139-149.
58. Myers R.D., Melchior C. Alcohol and alcoholism. role of serotonin Essman W.B. Serotonin in health and disease. Vol. 2. Physiological regulation and pharmacological action. 1977;373-430 Spectrum, New York.
59. Myers R.D., Privette T.H. A neuroanatomical substrate for alcohol drinking. identification of tetrahydropapaveroline (THP)- reactive sites in the rat brain Brain Res. Bull. 22:1989;899-911.
60. Myers R.D., Veale W.L. Alcohol preference in the rat. reduction following depletion of brain serotonin Science. 160:1968;1469-1471.
61. Myers, R. D.; Borg, S.; Mossberg, R.: Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 3:383-388; l986.
62. 2 antagonist amperozide. Alcohol. 10:1993;117-125.
63. Myers R.D., Robinson D.E. Tetrahydropapaveroline injected in the ventral tegmental area shifts dopamine efflux differentially in the shell and core of the nucleus accumbens of high ethanol preferring HEP rats. Alcohol. 18:1999;83-90.
64. Myers R.D., Robinson D., West M., Biggs T., McMillen B.A. Genetics of alcoholism. Rapid development of a new high ethanol preferring (HEP) strain of female and male rats Alcohol. 16:1998;343-357.
65. Neckers L., Whitesell L. Antisense technology. biological utility and practical considerations Am J. Physiol. 265:1993;L1-L12.
66. Nevo I., Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem. Int. 26:1995;305-336.
67. Noel M.B., Gratton A. Electrochemical evidence of increased dopamine transmission in prefrontal cortex and nucleus accumbens elicited by ventral tegmental mu-opioid receptor activation in freely behaving rats. Synapse. 21:1995;110-122.
68. O'Brien C.P. Treatment of alcoholism as a chronic disorder. Alcohol. 11:1994;433-437.
69. Ogawa S., Brown H.E., Okano H.J., Pfaff D.W. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Reg. Peptides. 59:1995;143-149.
70. 2 receptor antagonist. Brain Res. 31:1993;595-599.
71. Pasternak G.W., Standifer K.M. Mapping of opioid receptors using antisense oligodeoxynucleotides. correlating their molecular biology and pharmacology Trends Pharmacol. Sci. 16:1995;344-350.
72. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1986;Academic Press, Sydney.
73. Pfeffer A.O., Samson H.H. Effect of pimozide on home cage ethanol drinking in the rat. dependence on drinking session length Drug Alcohol Depend. 17:1986;47-55.
74. Phillips M.I., Gyurko R. In vivo applications of antisense oligonucleotides for peptide research. Reg. Peptides. 59:1995;131-141.
75. Phillips M.I., Gyurko R. Antisense oligonucleotides. new tools for physiology New Physiol. Sci. 12:1997;99-106.
76. 2 dopamine receptors. Mol. Pharmacol. 48:1995;730-737.
77. Ross D.W. Sense and antisense oligonucleotides. Arch. Pathol. Lab. Med. 114:1990;1296.
78. Rossi, G.; Pan, Y.; Cheng, J.; Pasternak, G. W.: Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54:375-379; 1994.
79. Rossi G.C., Su W., Leventhal L., Pasternak G. Antisense mapping DOR-1 in mice. further support for δ receptor subtypes Brain Res. 753:1997;176-179.
80. 2 autoreceptors in the motor actions of cocaine. Mol. Pharmacol. 46:1994;51-57.
81. 2 receptors in the limbic system. Alcohol Alcohol. 27:1992;127-130.
82. Stein C.A., Cheng Y. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science. 261:1993;1004-1012.
83. Stinus L., Koob G., Ling N., Bloom F., Le Moal M. Locomotor activation induced by infusion of endorphins into the ventral tegmental area. evidence for opiate-dopamine interactions Proc. Acad. Sci. 77:1980;2323-2327.
84. 2 receptor gene expression in rat lines selected for differences in voluntary alcohol consumption. Alc. Clin. Exp. Res. 18:1994;1029-1031.
85. Szklarczyk A., Kaczmarek L. Antisense oligodeoxyribonuleotides. stability and distribution after intracerebral injection into rat brain J. Neurosci. Meth. 60:1995;181-187.
86. Thuong N.T., Asseline U. Chemical synthesis of natural and modified oligodeoxynucleotides. Biochimie. 67:1985;673-684.
87. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry. 49:1992;876-880.
88. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1995;333-335.
89. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 152:1994;42-46.
90. Wehner J.M., Bowers B.J. Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Alc. Clin. Exp. Res. 19:1995;811-812.
91. 2 messenger RNA. Neurosci. 55:1993;607-612.
92. Weiss F., Mitchiner M., Bloom F., Koob G. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine and methysergide. Psychopharmacol. 101:1990;178-186.
93. Weiss F., Lorang M., Bollum F., Koob G. Ethanol self-administration stimulates dopamine release in the rat nucleus accumbens. genetic and motivational determinants J. Pharmacol. Exp. Ther. 267:1993;250-258.
94. Weiss F., Parsons L., Schulteis G., Hyytia P., Lorang M., Bloom F., Koob G. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J. Neurosci. 16:1996;3474-3485.
95. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Wallbridge S., Alger J., Neckers L. Stability, clearance and disposition of intraventricularly administered oligodeoxynucleotides. implications for therapeutic application with the central nervous system Proc. Natl. Acad. Sci. 90:1993;4665-4669.
96. Yaida Y., Nowak T.S. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Reg. Peptides. 59:1995;193-199.
97. Yoshida M., Yokoo H., Tanaka T., Mizoguchi K., Emoto H., Ishii H., Tanaka M. Facilitatory modulation of mesolimbic dopamine neuronal activity by a Mμ-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 624:1993;277-280.
98. 2 receptors. behavioral correlates Neurosci. Lett. 161:1993;223-226.
99. 1 dopamine receptor mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271:1994;1462-1470.
100. 2 dopamine receptors in mouse striatum. J. Pharm. Exp. Ther. 268:1994;1015-1023.
101. Zon G., Geiser T., Phosphorothioate oligonucleotides chemistry purification, analysis, scale-up and future directions. Anti Cancer Drug Des. 6:1991;539-568.
102. Zucker M. On finding all suboptimal foldings of an RNA molecule. Science. 244:1989;48-52.